Abstract
Coinfections of hepatitis C virus (HCV) and/or hepatitis B virus (HBV) with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) are associated with high morbidity and mortality and poor prognosis. The main objective of this study was to evaluate the prevalence of HCV and/or HBV coinfections among people who inject drugs (PWID) and female sex workers (FSWs) who live with HIV/AIDS worldwide. Data sources were searched from January 2008 to October 2018 in different databases, including PubMed, Scopus, Web of Science, Embase, and Ovid. Data were analyzed in Stata 14 software using the Metaprop command. The results showed that the prevalence of HCV among PWID and FSWs with HIV/AIDS was 72% (95% CI: 59%-83%) and 40% (95% CI: 0%-94%), respectively. The prevalence of HBV among PWID and FSWs with HIV/AIDS was 8% (95% CI: 5%-13%) and 2% (95% CI: 0%-7%), respectively, and the prevalence of HCV/HBV in PWID with HIV/AIDS was 11% (95% CI: 7%-15%). The highest prevalence of HCV was observed in PWID in the Eastern Mediterranean and Europe regions, and the lowest was observed in the Africa region. The South-East Asia region had the highest prevalence of HBV among PWID, and the Africa region had the lowest prevalence. The high prevalence of HCV coinfection among PWID and FSWs with HIV/AIDS was an alarming health problem and requires appropriate interventions. Therefore, considering that these populations are key populations for HCV elimination, it is recommended to screen them regularly for HCV. In addition, harm reduction and HBV vaccination should be carefully considered.
Similar content being viewed by others
Abbreviations
- HIV/AIDS:
-
Human immunodeficiency virus/acquired immune deficiency syndrome
- PWID:
-
People who inject drugs
- FSWs:
-
Female sex workers
- WHO:
-
World Health Organization
- PLWHA:
-
People who live with HIV/AIDS
References
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1736–1788
UNAIDS (2019) https://www.unaids.org/en/resources/fact-sheet.
WHO, HIV/AIDS (2019) https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids.
WHO h (2018) https://www.who.int/hepatitis/news-events/hbv-cure-overview/en.
WHO, C H (2019) https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c.
WHO, B H (2019) https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b.
UNAIDS WAeuDG, Switzerland: United Nations Programme on HIV/AIDS and World Health Organization (UNAIDS & WHO)
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K (2017) Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 5(12):e1192–e1207. https://doi.org/10.1016/S2214-109X(17)30375-3
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791):571–583
Mohsen A, Easterbrook P, Taylor C, Norris S (2002) Hepatitis C and HIV-1 coinfection. Gut 51(4):601–608
Konopnicki D, Mocroft A, De Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD (2005) Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids 19(6):593–601
Lacombe K, Rockstroh J (2012) HIV and viral hepatitis coinfections: advances and challenges. Gut 61(Suppl 1):i47–i58
Klein MB, Lalonde RG (1999) Suissa S (2003) The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33(3):365–372
Thio CL (2003) Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. In: Seminars in liver disease. vol 02. Copyright© 2002 by Thieme Medical Publishers, Inc., New York, pp 125–136
Hosseini Rad M, Jamshidi Makiani M, Kalantari S, Sohrabi S, Ahmadniya H, Zanganeh M (2017) The study of seroprevalence of hepatitis B and hepatitis C and behavioral factors in HIV patients referred to the consultation clinics of Tehran Behavioral Diseases Health Center. Med Sci J Islamic Azad Univ Tehran Med Branch 27(1):53–61
Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360(9349):1921–1926
Schüttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S (2002) Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 37(6):855–862
Drosten C, Nippraschk T, Manegold C, Meisel H, Brixner V, Roth WK, Apedjinou A, Günther S (2004) Prevalence of hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus. J Clin Virol 29(1):59–68
Sulkowski MS (2008) Viral hepatitis and HIV coinfection. J Hepatol 48(2):353–367
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15):2008–2012
Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH (2017) Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy 45:64–69
Khatib A, Matiko E, Khalid F, Welty S, Ali A, Othman A, Haji S, Dahoma M, Rutherford G (2017) HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar. BMC Public Health 17(1):917
Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, Nash D, Perlman DC (2015) Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006–2013. Drug Alcohol Depend 152:194–200
Hsieh M-H, Tsai J-J, Hsieh M-Y, Huang C-F, Yeh M-L, Yang J-F, Chang K, Lin W-R, Lin C-Y, Chen T-C, Huang J-F, Dai C-Y, Yu M-L, Chuang W-L (2014) Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection. PLoS ONE 9(4):e94791. https://doi.org/10.1371/journal.pone.0094791
Kuniholm MH, Aladashvili M, Rio CD, Stvilia K, Gabelia N, Chitale RA, Tsertsvadze T, Nelson KE (2008) Not all injection drug users are created equal: heterogeneity of HIV, hepatitis C virus, and hepatitis B virus infection in Georgia. Subst Use Misuse 43(10):1424–1437
Alaei A, Alaei K, Waye K, Tracy M, Nalbandyan M, Mutlu E, Cetin M (2017) Hepatitis C infection and other drug-related harms among inpatients who injected drugs in Turkey. J Viral Hepatitis 24(6):496–505
Pilon R, Leonard L, Kim J, Vallee D, De Rubeis E, Jolly AM, Wylie J, Pelude L, Sandstrom P (2011) Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs. PLoS ONE 6(7):e22245
Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, Anand S, Kumar MS, Latkin C (1999) Solomon S (2008) High prevalence of HIV, HIV/hepatitis C virus co-infection and risk behaviors among IDUs in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 49(3):327
Jõgeda EL, Avi R, Pauskar M, Kallas E, Karki T, Des Jarlais D, Uusküla A, Toompere K, Lutsar I, Huik K (2018) Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. J Med Virol 90(11):1779–1783
Ruiseñor-Escudero H, Wirtz AL, Berry M, Mfochive-Njindan I, Paikan F, Yousufi HA, Yadav RS, Burnham G, Vu A (2014) Risky behavior and correlates of HIV and hepatitis C virus infection among people who inject drugs in three cities in Afghanistan. Drug Alcohol Depend 143:127–133
Davoodian P, Dadvand H, Mahoori K, Amoozandeh A (2002) Salavati A (2009) Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran. Braz J Infect Dis 13(5):356–358
Demissie M, Johnston LG, Muleta M, Desyebelew D, Belete W, G/Egxiabehre A, Gezahegn N, Kassa D, Aseffa Y (2018) Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia. Afr J AIDS Res 17(3):259–264
Mansha S, Imran M, Shah A, Jamal M, Ahmed F, Atif M, Saleem M, Safi SZ, Fatima Z, Bilal Waqar A (2017) Hepatitis B and C virus infections among human immunodeficiency virus-infected people who inject drugs in Lahore, Pakistan. Viral Immunol 30(5):366–370. https://doi.org/10.1089/vim.2016.0144
Mahanta J, Borkakoty B, Das HK, Chelleng PK (2009) The risk of HIV and HCV infections among injection drug users in northeast India. AIDS Care 21(11):1420–1424
Garfein RS, Rondinelli A, Barnes RF, Cuevas J, Metzner M, Velasquez M, Rodriguez D, Reilly M, Xing J, Teshale EH (2013) HCV infection prevalence lower than expected among 18–40-year-old injection drug users in San Diego, CA. J Urban Health 90(3):516–528
McFall AM, Solomon SS, Lucas GM, Celentano DD, Srikrishnan AK, Kumar MS, Mehta SH (2017) Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study. Addiction 112(8):1480–1487
da Silva CM, de Peder LD, Guelere AM, Horvath JD, Silva ES, Teixeira JJV, Bertolini DA (2018) Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil. PLoS ONE 13(9):e0203272
Ionita G, Malviya A, Rajbhandari R, Schluter WW, Sharma G, Kakchapati S, Rijal S, Dixit S (2017) Seroprevalence of hepatitis B virus and hepatitis C virus co-infection among people living with HIV/AIDS visiting antiretroviral therapy centres in Nepal: a first nationally representative study. Int J Infect Dis 60:64–69
Dong Y, Qiu C, Xia X, Wang J, Zhang H, Zhang X, Xu J (2015) Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study. Adv Virol 160(4):929–936
Yan Y, Gao Y, Sun X, Wang W, Huang X, Zhang T, Li M, Zang C, Li Z, Wu H (2011) Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients. Epidemiol Infect 139(3):354–360
Schuelter-Trevisol F, Custodio G, Silva ACBd, Oliveira MBd, Wolfart A, Trevisol DJ (2013) HIV, hepatitis B and C, and syphilis prevalence and coinfection among sex workers in Southern Brazil. Rev Soc Bras Med Trop 46(4):493–497
Johnston LG, Corceal S (2013) Unexpectedly high injection drug use, HIV and hepatitis C prevalence among female sex workers in the Republic of Mauritius. AIDS Behav 17(2):574–584
Haussig JM, Nielsen S, Gassowski M, Bremer V, Marcus U, Wenz B, Bannert N, Bock C-T, Zimmermann R, group Ds (2018) A large proportion of people who inject drugs are susceptible to hepatitis B: results from a bio-behavioural study in eight German cities. Int J Infect Dis 66:5–13
Shethwala ND, Mulla SA, Kosambiya J, Desai VK (2009) Sexually transmitted infections and reproductive tract infections in female sex workers. Indian J Pathol Microbiol 52(2):198
Kotaki T, Khairunisa SQ, Sukartiningrum SD, Arfijanto MV, Utsumi T, Normalina I, Handajani R, Widiyanti P, Rusli M, Rahayu RP (2013) High prevalence of HIV-1 CRF01_AE viruses among female commercial sex workers residing in Surabaya, Indonesia. PLoS ONE 8(12):e82645
Soriano V, Barreiro P, Nuñez M (2006) Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 57(5):815–818
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P (2016) Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 16(7):797–808
Johnston L, Saumtally A, Corceal S, Mahadoo I, Oodally F (2011) High HIV and hepatitis C prevalence amongst injecting drug users in Mauritius: findings from a population size estimation and respondent driven sampling survey. Int J Drug Policy 22(4):252–258
Webale MK, Budambula V, Lihana R, Musumba FO, Nyamache AK, Budambula NL, Ahmed AA, Ouma C, Were T (2015) Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and Non-injection drug users from coastal Kenya. BMC Infect Dis 15(1):299
Origer A, Schmit J-C (2012) Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence. J Epidemiol Community Health 66(1):64–68
Acknowledgements
This work was supported by the Deputy of Research of Kurdistan University of Medical Sciences. This article is a part of master’s degree dissertation in epidemiology in 2018 entitled “Prevalence of HIV, Hepatitis C and B co-infection in People Who Inject Drug (PWID) and Female Sex Workers (FSWs) Worldwide; A Systematic Review and Meta-Analysis” which was recorded under code: IR.MUK.REC.1397/275.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Handling Editor: YiMing Shao.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rashti, R., Alavian, S.M., Moradi, Y. et al. Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. Arch Virol 165, 1947–1958 (2020). https://doi.org/10.1007/s00705-020-04716-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-020-04716-1